AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home . Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San... Read More

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9... Read More

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc ( OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to:... Read More

AGOURA HILLS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that Product Manager Scott Myers, working through GMP Biotechnology Limited, our 45% Joint Venture with Dragon Capital Limited, will be presenting at the 2 nd Global Summit on Artificial Intelligence. The summit, which is being hosted digitally, is centered on the... Read More

AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary. Title: TGFB2 therapeutic for the treatment of CRC, GBM, and PDAC Anirudh Kolanu, K. Khuranu, A. Mehta, T. Sanil1, G. Trieu, and Dr. Vuong... Read More

AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with more than 18,500 industry leaders from across the globe. About... Read More

AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: e16318. Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in patients with pancreatic adenocarcinoma harboring unresectable tumors treated with... Read More

AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: Nanomedicines: Past, Present, Future. For additional information please go to: https://nexus-conference.com/ddnwest/ . Dr. Hu is an experienced Biomaterial Scientist with expertise in nanomedicine, biologics,... Read More

AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (“Mosaic”) under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting... Read More

AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas: Past, Present,... Read More

AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be obtained at www.stop-pc.com . An explainer video is available at https://www.youtube.com/watch?v=C4ZsE3fulIU . STOP-PC is a Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide... Read More

AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients in the Special Issue Gliomas: Signaling Pathways, Molecular Mechanisms and... Read More

AGOURA HILLS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC. Situated in San Diego biotechnology hub, this cutting-edge, AI-driven facility marks a pivotal expansion in the company's clinical... Read More

AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its Chief Executive Officer (“CEO”), Dr. Vuong Trieu, will be a featured speaker at the upcoming Ibero-American Chatbot and Conversational AI Summit. Dr. Trieu will be discussing the Company’s proprietary chatbots, which are a part of the Orion AI Technology suite... Read More

R&D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (“JV”) G&A cost significantly lower by over approximately $0.5 million. Net loss reduced by approximately $0.9 million Operating expenses reduced by approximately $0.5 million when comparing Q3 2023 versus Q3 2022 AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.... Read More

AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc ( OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences Review, Cancer Immunology Edition and has been awarded a Top Cancer Immunotherapy Solutions Provider 2023 with other aluminous organizations. This edition features the Company’s science and planned clinical trials across multiple... Read More

AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP Biotechnology Limited’s wholly owned subsidiary – Sapu Bioscience, LLC (“Sapu”), together with with Cromos Pharma, LLC (“Cromos”), a US-based international contract research organization (“CRO”), to conduct Sapu’s registrational trial... Read More

AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc ( OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press releases (“PR”) chatbot. This chatbot is set to redefine user interaction by providing interactive responses to all our press releases through April 24, 2023. Our PR chatbot is open to all users, with no restriction on token holder... Read More

AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“ Oncotelic ” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases such as Parkinson's Disease and various forms of cancer, is thrilled to announce their participation in the BIO International Convention. The Company's presentation is readily accessible at... Read More

AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary SEC chatbot, utilizing our DAO token (PDAO) and Artificial Intelligence (AI). This chatbot allows users to receive conversational responses about the Company's SEC filings filed as of April 12, 2023. Only holders of the Pet2DAO... Read More

The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and development industry. AGOURA HILLS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ”, “ We ” or the “ Company ”) ( OTCQB:OTLC ) announced today a strategic partnership with Vectara, a company specializing in innovative Natural Language Understanding (NLU)... Read More

AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) ( OTCQB: OTLC ) is providing a summary of its financial results for the year ended December 31, 2022 (“ FY 202 2 ”) as compared to the prior year ended December 31, 2021 (“ FY 202 1 ”). We are also providing updates on our product and therapeutic development initiatives and other corporate... Read More

AGOURA HILLS, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, Pancreatic Ductal Adenocarcinoma, Diffuse Intrinsic Pontine Glioma, and COVID-19, today announced the process for the shareholders of the Company for the release of Pet2DAO LLC (“Pet2DAO”) tokens called... Read More

PDAO is to Revolutionize Decentralized Autonomous Organization AGOURA HILLS, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, today announced the launch of its Pet2DAO website in preparation for previously announced distribution of PDAO tokens to shareholders. The website can be access at https://www.pet2dao.com/... Read More

The TGFβ1 and TGFβ3 isoforms are predictive Validation of TGFβ 2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, pancreatic ductal adenocarcinoma, diffuse intrinsic pontine gliomas (“DIPG”), and COVID-19, today announced the... Read More

AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced the initiation of its second investigator initiated studies (IIS) in a series of planned clinical studies. We have submitted to US FDA a protocol for the study... Read More

AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of its JV this year, today announced that it has submitted a clinical study protocol to the US Food and Drug Administration (“FDA”) for the initiation of a Phase 2b/3 Trial (designated "P201") for OT-101, the Company's transforming... Read More

PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of its JV this year, today announced the launch of Pet2DAO Inc. (Pet2Dao), a wholly owned subsidiary of Oncotelic, and its associated token PDAO. Pet2DAO is a DAO... Read More

JV continues to advance to its IPO OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023 OT-101 commercialization effort expanding on multiple fronts M anufacturing and DAO capabilities being built with platform launched slated for 2023 AGOURA HILLS, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage cancer... Read More

Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, today announced today announced it presented new clinical confirming TGF-β2 as the appropriate target for gliomas at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer... Read More

AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced the publication of the presentation materials from the Society for Neuro-Oncology (“SNO”) 27th Annual Meeting held in Tampa Bay, FL on November 16th-20th, 2022... Read More

R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint venture G&A cost reduced by approximately 50% Net loss reduced by approximately $1.0 million for the three months ended September 30, 2022, compared to the same period of 2021 Operating expenses reduced by approximately $1.2 million when comparing Q3 2022 versus Q3 2021 AGOURA HILLS, Calif., Nov. 21, 2022 (GLOBE... Read More

Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), through its wholly owned subsidiary Oncotelic Inc., a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID, today announced the approval of a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response... Read More

Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), directly and / or through its wholly owned subsidiaries Oncotelic Inc. and PointR Data Inc., a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced the formation of an animal health division. One of the objectives being evaluated by the Company within the new initiative... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease, Pancreatic Cancer, and DIPG, today announced that the Company will be presenting at the upcoming SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, MA. Abstract Number: 599 Title: Mechanism of Action for OT-101 TGF-ß immunotherapy Session Date:... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease and DIPG, today announced that the Company will have two poster presentations at the upcoming 2022 Society for Neuro-Oncology (SNO) Annual Meeting on November 16-20, 2022, Tampa Bay, Florida. Abstract Number: DDEL-16 Title: Delivery of OT-101 - TGF-2 Antisense- for... Read More

Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 million Reduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) (OTCQB: OTLC ) today announced financial results for the three months ended June 30, 2022 (“ Q2 2022 ”) as compared to the three months ended June 30, 2021 (“ Q2 2021 ”).... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company will be participating at Biotechgate Digital Partnering – a business development & licensing event - Aug 29 - Sep 2, 2022. An updated investor slide deck will be available at our website after the event. About... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at 7th JCA-AACR Special Joint Conference (July 8-10, 2022) is now available at https://www.oncotelic.com/wp-content/uploads/2022/07/JCA-2022.pptx.pdf and https://www.youtube.com/watch?v=D9h7ExvUUVs.... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at BIO International Convention is now available at https://www.oncotelic.com/wp-content/uploads/2022/06/BIO-2022-digital-slides.pdf . The JVCo IPO- is on track for 2023 with anticipated minimum... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the Food and Drug Administration. Oncotelic is initiating a Phase 2 Investigator Initiated Study (IIS) clinical trial in patients... Read More

Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) ( OTCQB: OTLC ) today announced financial results for the three months ended March 31, 2022 (“ Q1 2022 ”) as compared to the three months ended March 31, 2021 (“ Q1 2021 ”), an update on its product and therapeutic development initiatives and other corporate updates. The financial results were based on the Quarterly Report on Form 10-Q filed with the... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced the Company will be presenting at the BIO International Convention taking place in San Diego, California between June 13 - 16, 2022. Dr. Vuong Trieu, CEO and Chairman, will be presenting an overview of the Oncotelic’s pipeline,... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882 entitled “USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS” by the US Patent Office. The claims of the patent are directed to a pharmaceutical composition for producing an anti-tumor effect in a subject suffering from cancer or a tumor, comprising a Vascular... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB :OTLC ), today announced the appointment of Dr. Seymour Fein as its Chief Regulatory Officer. Dr. Fein will guide the company registration trials through their global submissions including FDA, EMA, and NMPA. “With the completion of the Joint Venture with Dragon Overseas Capital Limited for OT-101, Dr. Fein has the skill sets necessary at our current stage of... Read More

Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company” or “We” ) (OTCQB :OTLC ), today announced the appointment of Dr. Fatih Uckun as its Chief Medical Officer. Dr. Uckun will be responsible for execution of internal company led registrational trials. “The addition of Dr. Uckun to our executive team, comes at a critical time for Oncotelic. We have made significant inroads toward our goal of developing OT-101 as... Read More

Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) (OTCQB: OTLC ) today announced financial results for the full year ended December 31, 2021 (“ FY 202 1 ”) as compared to the full year ended December 31, 2020 (“ FY 2020 ”), an update on its product and therapeutic development initiatives and other corporate updates. The financial results were based on the 2021 Annual Report on Form 10-K filed with the... Read More

Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) (OTCQB :OTLC ), issued the following shareholder letter today. Dear Fellow Shareholders, We would like to thank you for being part of our mission at Oncotelic which is to develop treatments for cancer patients that have limited options. Our efforts include pursuing broad applications of our technology as well as the treatment of cancer types that are given orphan... Read More

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), today announced the formation of a Joint Venture (“JV”) with Dragon Overseas Capital Limited (“Dragon Overseas”). Dragon Overseas is a company affiliated with Golden Mountain Partners, LLC. “I am excited to announce that, together with our partner Dragon Overseas, we have formed a JV for the discovery, development and commercialization of TGF-β... Read More

● OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β ● OT-101 has completed over six clinical trials against solid tumors with good efficacy ● OT-101 is currently undergoing a phase 1b trial in combination with IL-2 ● Multiple trials combining OT-101 with pembrolizumab are in development ● OT-101 has also completed a phase 2 trial against COVID with good efficacy Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”)... Read More

Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. as a speaker at the upcoming annual Evolution Summit taking place in Los Angeles this month. Dr Anthony E. Maida focused on the immunotherapy of cancer and infectious disease. He was formerly the Senior Vice President –... Read More

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against solid tumors with good efficacy OT-101 is currently undergoing a phase 1b trial in combination with IL-2 Multiple trials combining OT-101 with pembrolizumab are in development OT-101 has also completed a phase 2 trial against COVID with good efficacy Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) (... Read More

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against solid tumors with good efficacy OT-101 is currently undergoing a phase 1b trial in combination with IL-2 Multiple trials combining OT-101 with pembrolizumab are in development OT-101 has also completed a phase 2 trial against COVID with good efficacy Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” )... Read More

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against solid tumors with good efficacy OT-101 is currently undergoing a phase 1b trial in combination with IL-2 Multiple trials combining OT-101 with pembrolizumab are in development OT-101 has also completed a phase 2 trial against COVID with good efficacy Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) (... Read More

Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has submitted a clinical study protocol to the United States Food and Drug Administration (“US FDA”) for the initiation of a Phase 1 Clinical Trial for CA4P, the Company’s Vascular Disrupting Agent, in combination with Anti-PD-1 (pembrolizumab) as a... Read More

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients. Fatality in hospital... Read More

Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will present at the upcoming 2 nd Annual TGF-β for Immuno-Oncology Drug Development Summit ( tgf-beta-summit.com ), which will take place virtually from January 25, 2022 to January 27,... Read More

Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase 2 Trial (designated “M201”) for OT-101, the Company’s TGF-β inhibitor, in combination with Anti-PD-1 (Pembrolizumab/Keytruda ® ) as a treatment for patients with Malignant... Read More

Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB: OTLC ) today announced financial results for the third quarter ended September 30, 2021 (“ Q3 202 1 ”), as well as an update on its product and therapeutic development initiatives and other corporate updates. Q3 202 1 compared to Q3 2020 Financial Results Overview – ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS FOR... Read More

Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that its COVID-19 trial (“C001”) for OT-101 has successfully met its safety and efficacy endpoints. OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in... Read More

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, provided an update on ongoing OT-101/IL-2 combination trial (the “Trial”), which has now successfully completed the safety evaluation of its safety cohort, allowing for further expansion of its clinical program into phase 2 clinical trials and higher doses. The Trial, Multi-center,... Read More